Adherence to Long-Term Therapies - Evidence for Action
(2003; 211 pages) View the PDF document
Table of Contents
View the documentPreface
View the documentAcknowledgements
View the documentScientific writers
View the documentIntroduction
View the documentTake-home messages
Open this folder and view contentsSection I - Setting the scene
Open this folder and view contentsSection II - Improving adherence rates: guidance for countries
Close this folderSection III - Disease-Specific Reviews
Open this folder and view contentsChapter VII - Asthma
Open this folder and view contentsChapter VIII - Cancer (Palliative care)
Open this folder and view contentsChapter IX - Depression
Open this folder and view contentsChapter X - Diabetes
Open this folder and view contentsChapter XI - Epilepsy
Close this folderChapter XII - Human immunodeficiency virus and acquired immunodeficiency syndrome
View the document1. Types of nonadherence
View the document2. Challenges in assessing adherence
View the document3. Predictors of adherence
View the document4. A framework for interventions to increase adherence
View the document5. Conclusions
View the document6. References
Open this folder and view contentsChapter XIII - Hypertension
Open this folder and view contentsChapter XIV - Tobacco smoking cessation
Open this folder and view contentsChapter XV - Tuberculosis
Open this folder and view contentsAnnexes
Open this folder and view contentsWhere to find a copy of this book

6. References

1. Bedell SE et al. Discrepancies in the use of medications: their extent and predictors in an outpatient practice. Archives of Internal Medicine, 2000, 160: 2129 - 2134.

2. Lerner BH, Gulick RM, Dubler NN. Rethinking nonadherence: historical perspectives on triple-drug therapy for HIV disease. Annals of Internal Medicine, 1998, 129: 573 - 578.

3. Stephenson BJ et al. Is this patient taking the treatment as prescribed? Journal of the American Medical Association, 1993, 269: 2779 - 2781.

4. Bangsberg DR et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS, 2000, 14: 357 - 366.

5. Montaner JSG et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Journal of the American Medical Association, 1998, 279: 930 - 937.

6. Paterson DL et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 2000, 133: 21 - 30.

7. Boden D et al. HIV-1 drug resistance in newly infected individuals. Journal of the American Medical Association, 1999, 282: 1135 - 1141.

8. Hecht FM et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. New England Journal of Medicine, 1998,339: 307-311.

9. Little SJ et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. Journal of the American Medical Association, 1999, 282: 1142 - 1149.

10. Little SJ et al. Antiretroviral drug susceptibility and response to initial therapy among recently HIV-infected subjects in North America. In: Program and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA, Foundation for Retrovirology and Human Health, 2001: 273.

11. Hammer SM et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. New England Journal of Medicine, 1997, 337: 725 - 733.

12. Palella FJJ et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine, 1998, 338: 853 - 860.

13. Chesney MA, Morin M, Sherr L. Adherence to HIV combination therapy. Social Science & Medicine, 2000, 50: 1599 - 1605.

14. Ho DD et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature, 1995, 373: 123 - 126.

15. Perelson AS et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science, 1996, 271: 1582 - 1586.

16. Finzi D et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science, 1997, 278: 1295 - 1300.

17. Zhang L et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. New England Journal of Medicine, 1999, 340: 1605 - 1613.

18. Voelker R. HIV drug resistance. Journal of the American Medical Association, 2000, 284: 169.

19. Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. American Journal of Medicine, 1997, 102: 43 - 49.

20. Gao X, Nau DP. Congruence of three self-report measures of medication adherence among HIV patients. Annals of Pharmacotherapy, 2000, 34: 1117 - 1122.

21. Waterhouse DM et al. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. Journal of Clinical Oncology, 1993, 11: 1189 - 1197.

22. Rand CS et al. Metered-dose inhaler adherence in a clinical trial. American Review of Respiratory Disease, 1992, 146: 1559 - 1564.

23. Haynes RB, McKibbon KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet, 1996, 348: 383 - 386.

24. Wagner GJ, Rabkin JG. Measuring medication adherence: are missed doses reported more accurately then perfect adherence? AIDS Care, 2000, 12: 405 - 408.

25. Du Pasquier-Fediaevsky L, Tubiana-Rufi N. Discordance between physician and adolescent assessments of adherence to treatment: influence of HbA1c level. Diabetes Care, 2002, 22: 1445 - 1449.

26. Gilbert JR et al. Predicting compliance with a regimen of digoxin therapy in family practice. Canadian Medical Association, 1980, 123: 119 - 122.

27. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clinical Infectious Diseases, 2000, 30: S171 - 176.

28. Bartlett J, DeMasi R, Quinn J, Moxham C, Rousseau F. Correlation between antiretroviral pill burden and durability of virologic response: a systematic overview. Program and abstracts of the XIII International AIDS Conference; 9 - 14 July, 2000; Durban, South Africa. Abstract ThPeB4998.

29. Carr A. HIV protease inhibitor-related lipodystrophy syndrome. Clinical Infectious Diseases, 2000, 30: S135 - S142.

30. D'Arminio A et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. AIDS, 2000, 14: 499 - 507.

31. Kaul DR et al. HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications. Pharmacotherapy, 1999, 19: 281 - 298.

32. Gao X et al. The relationship of disease severity, health beliefs and medication adherence among HIV patients. AIDS Care, 2000, 12: 387 - 398.

33. Eldred LJ et al. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. Journal of Acquired Immune Deficiency Syndromes, 1998, 18: 117 - 125.

34. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clinical Therapeutics, 1984, 6: 592 - 599.

35. Wenger N et al. Patient characteristics and attitudes associated with antiretroviral (AR) adherence. Abstract No. 98. Presented at the VI Conference on retrovirus and opportunistic infections. Washington DC, 1999.

36. Halkitis P et al. Characteristics of HIV antiretroviral treatments and adherence in an ethnically-diverse sample of men who have sex with men. AIDS Care (in press).

37. Stone VE et al. HIV/AIDS patients' perspectives on adhering to regimens containing protease inhibitors. Journal of General Internal Medicine, 1998, 13: 586 - 593.

38. Stone V. Strategies for optimizing adherence to highly active antiretroviral therapy: Lessons from research and clinical practice. Clinical Infectious Diseases, 2001, 33: 865 - 872.

39. Nieuwkerk PT, Gisolf EH, Wu AW. Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy. AIDS, 2000, 14: 181 - 187.

40. Mocroft A et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS, 2001, 15: 185 - 194.

41. Catz SL et al. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychology, 2000, 19: 124 - 133.

42. Duran S et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clinical Trials, 2001, 2: 38 - 45.

43. Kasper TB, Arboleda CH, Halpern M. The impact of patient perceptions of body shape changes and metabolic abnormalities on antiretroviral therapy. Program and abstracts of the XIII International AIDS Conference; July 9-14, 2000; Durban, South Africa. Abstract WePpB1380.

44. Graham NM. Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review. Journal of Acquired Immune Deficiency Syndromes, 2002, 25: S4 - S11.

45. Mauss S. HIV-associated lipodystrophy syndrome. AIDS, 2000, 14: S197 - S207.

46. Carr A et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS, 1998, 12: F51 - F58.

47. Gervasoni C, Ridolfo AL, Trifirò G. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS, 1999, 13: 465 - 471.

48. Mynarcik DC et al. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. Journal of Acquired Immune Deficiency Syndromes, 2000, 25: 312 - 321.

49. Chesney MA. Adherence to drug regimens: a learned skill. Improving the Management of HIV Disease, 1997, 5: 12.

50. Malow R et al. A Cognitive-behavioral intervention for HIV+ recovering drug abusers: The 2000-05 NIDA-funded AIDS Prevention Center study. Psychology & AIDS Exchange, 2001, 30: 23 - 26.

51. Ostrop NJ, Hallett KA, Gill MJ. Long-term patient adherence to antiretroviral therapy. Annals of Pharmacotherapy, 2000, 34: 703 - 709.

52. Mocroft A et al. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. Journal of Acquired Immune Deficiency Syndromes, 1999, 22: 369 - 378.

53. Chesney MA et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. AIDS Care, 2000, 12: 255 - 266.

54. Gordillo V et al. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS, 1999, 13: 1763 - 1769.

55. Holzemer WL et al. Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care and STDs, 1999, 13: 185 - 197.

56. Murphy DA et al. Antiretroviral medication adherence among the REACH HIV infected adolescent cohort in the USA. AIDS Care, 2001, 13: 27 - 40.

57. Singh BN. Effects of food on clinical pharmacokinetics. Clinical Pharmacokinetics, 1999, 37: 213 - 255.

58. Dunbar-Jacob J, Burke LE, Pyczynski S. Clinical assessment and management of adherence to medical regimens. In: Nicassio PM, Smith TW, eds. Managing chronic illness: A biopsychosocial perspective. Washington, DC, American Psychological Association, 1995: 313 - 349.

59. Morse EV et al. Determinants of subject compliance within an experimental anti-HIV drug protocol. Social Science & Medicine, 1991, 32: 1161 - 1167.

60. Stall R et al. Decisions to get HIV tested and to accept antiretroviral therapies among gay/bisexual men: Implications for secondary prevention efforts. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 1996, 11: 151 - 160.

61. Chesney M et al. Adherence: A necessity for successful HIV combination therapy. AIDS, 1999, 13: S271 - S278.

62. Panel on Clinical Practices for Treatment of HIV. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents (NIH 2002). Morbidity and Mortality Weekly Report. Atlanta, GA, Centers for Diseases Control and Prevention, 2002, Vol. 51, No. RR07.

63. Siegel K, Karus D, Schrimshaw EW. Racial differences in attitudes toward protease inhibitors among older HIV-infected men. AIDS Care, 2000, 12: 423 - 434.

64. Ng JJ et al. Adherence to highly active antiretroviral therapy in substance abusers with HIV/AIDS. Journal of General Internal Medicine, 2000, 15: 165.

65. Samet JH et al. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. American Journal of Medicine, 1992, 92: 495 - 502.

66. Sbarbaro JA. The patient - physician relationship: compliance revisited. Annals of Allergy, 1990, 64: 321 - 331.

67. Hedge B, Petrak JA. Take as prescribed: a study of adherence behaviours in people taking anti-retroviral medications [abstract 32346].Abstract Book. Presented at the 12th World AIDS Conference; 28 June - 3 July, 1998. Geneva, 1998: 590 - 591.

68. Caldwell JR. Drug regimens for long-term therapy of hypertension. Geriatrics, 1976, 31: 115 - 119.

69. Fischl MA. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection. AIDS, 1999, 13: S49 - S59.

70. Reiter GS et al. Elements of success in HIV clinical care: multiple interventions that promote adherence. Topics in HIV Medicine, 2002, 8: 21-30.

71. Farmer P et al. Community-based treatment of advanced HIV disease: introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy). Bulletin of the World Health Organization, 2001, 79: 1145 - 1151.

72. Farmer P et al. Community-based approaches to HIV treatment in resource-poor settings. Lancet, 2001, 358: 404-409.

73. Singler J, Farmer P. Treating HIV in resource-poor settings. Journal of the American Medical Association, 2002, 288: 1652 - 1653.

74. Pablos-Mendez A. AIDS care is learnt by doing it. Bulletin of the World Health Organization, 2001, 79: 1153 - 1154.

to previous section
to next section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 6, 2017